What is Oasis Diagnostics?
Oasis Diagnostics Corporation is dedicated to advancing modern medicine through the development of innovative, non-invasive saliva collection tools and testing devices. Their product portfolio features standardized saliva collection kits engineered for the precise gathering of RNA, DNA, and other critical biomarkers, serving the demanding requirements of the life science and research communities. By offering cost-effective and minimally invasive diagnostic solutions, Oasis Diagnostics addresses key needs within the in vitro diagnostics market, including molecular diagnostics and point-of-care testing. The company leverages proprietary and patented technologies to improve public health outcomes and overall wellness.
How much funding has Oasis Diagnostics raised?
Oasis Diagnostics has raised a total of $733K across 1 funding round:
Grant
$733K
Grant (2013): $733K with participation from National Institutes of Health
Key Investors in Oasis Diagnostics
National Institutes of Health
The National Institutes of Health (NIH), founded in 1887 and based in Bethesda, Maryland, is a primary agency of the U.S. Department of Health and Human Services, responsible for biomedical and health-related research.
What's next for Oasis Diagnostics?
The substantial enterprise-level funding context suggests Oasis Diagnostics is poised for significant scaling and market penetration. With a foundation built on research grants and strategic investments, the company is likely to expand its product development pipeline, enhance manufacturing capabilities, and broaden its commercial reach. Future initiatives may focus on further validating their diagnostic technologies for a wider range of clinical applications and strengthening partnerships within the healthcare ecosystem to drive adoption of their non-invasive testing solutions.
See full Oasis Diagnostics company page
